Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?

Marko Babjuk; Maximilian Burger; Eva M. Compérat; Paolo Gontero; Hugh A. Mostafid; Joan Palou; Bas W.G. van Rhijn; Morgan Rouprêt; Shahrokh F. Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José L. Dominguez-Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup

doi:10.1016/j.euf.2018.07.023

Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?

Marko Babjuk, Maximilian Burger, Eva M. Compérat, Paolo Gontero, Hugh A. Mostafid, Joan Palou, Bas W.G. van Rhijn, Morgan Rouprêt, Shahrokh F. Shariat, Richard Sylvester, Richard Zigeuner, Otakar Capoun, Daniel Cohen, José L. Dominguez-Escrig, Virginia Hernández, Benoit Peyronnet, Thomas Seisen, Viktor Soukup

Research output: Contribution to journal › Article › Research › peer-review

Abstract

© 2018 European Association of Urology An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3 cm, and single recurrent papillary tumours recurring >1 yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy–guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. Patient summary: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours. An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours.

Original language	English
Pages (from-to)	525-528
Journal	European Urology Focus
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/j.euf.2018.07.023
Publication status	Published - 1 Jul 2018

Keywords

Bladder cancer
Indication
Non–muscle-invasive
Single postoperative instillation of chemotherapy

Access to Document

10.1016/j.euf.2018.07.023

Fingerprint Dive into the research topics of 'Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?'. Together they form a unique fingerprint.

Cite this

Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, H. A., Palou, J., van Rhijn, B. W. G., Rouprêt, M., Shariat, S. F., Sylvester, R., Zigeuner, R., Capoun, O., Cohen, D., Dominguez-Escrig, J. L., Hernández, V., Peyronnet, B., Seisen, T., & Soukup, V. (2018). Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered? European Urology Focus, 4(4), 525-528. https://doi.org/10.1016/j.euf.2018.07.023

Babjuk, Marko ; Burger, Maximilian ; Compérat, Eva M. ; Gontero, Paolo ; Mostafid, Hugh A. ; Palou, Joan ; van Rhijn, Bas W.G. ; Rouprêt, Morgan ; Shariat, Shahrokh F. ; Sylvester, Richard ; Zigeuner, Richard ; Capoun, Otakar ; Cohen, Daniel ; Dominguez-Escrig, José L. ; Hernández, Virginia ; Peyronnet, Benoit ; Seisen, Thomas ; Soukup, Viktor. / Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?. In: European Urology Focus. 2018 ; Vol. 4, No. 4. pp. 525-528.

@article{0f2da1595f4f41b48025d29e0e99feea,

title = "Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?",

abstract = "{\textcopyright} 2018 European Association of Urology An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3 cm, and single recurrent papillary tumours recurring >1 yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy–guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. Patient summary: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours. An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non–muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours.",

keywords = "Bladder cancer, Indication, Non–muscle-invasive, Single postoperative instillation of chemotherapy",

author = "Marko Babjuk and Maximilian Burger and Comp{\'e}rat, {Eva M.} and Paolo Gontero and Mostafid, {Hugh A.} and Joan Palou and {van Rhijn}, {Bas W.G.} and Morgan Roupr{\^e}t and Shariat, {Shahrokh F.} and Richard Sylvester and Richard Zigeuner and Otakar Capoun and Daniel Cohen and Dominguez-Escrig, {Jos{\'e} L.} and Virginia Hern{\'a}ndez and Benoit Peyronnet and Thomas Seisen and Viktor Soukup",

year = "2018",

month = jul,

day = "1",

doi = "10.1016/j.euf.2018.07.023",

language = "English",

volume = "4",

pages = "525--528",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

number = "4",

}

Babjuk, M, Burger, M, Compérat, EM, Gontero, P, Mostafid, HA, Palou, J, van Rhijn, BWG, Rouprêt, M, Shariat, SF, Sylvester, R, Zigeuner, R, Capoun, O, Cohen, D, Dominguez-Escrig, JL, Hernández, V, Peyronnet, B, Seisen, T & Soukup, V 2018, 'Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?', European Urology Focus, vol. 4, no. 4, pp. 525-528. https://doi.org/10.1016/j.euf.2018.07.023